Active substance
Ferrous fumarate
- SFDA 2
- NHS prices 5
- Safety 3
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Ferrous Fumarate | 200 mg | Film-coated tablet · Oral use | 60 Blister | SAR 23.15 | Generic · OTC | REMEDICA | Valid |
| FUMAFER 200MG TABLET | 200 mg | Tablet · Oral use | 100 Blister | SAR 10.60 | NCE · OTC | sanofi-aventis | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
IRON DEFICIENCY ANEMIA
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Ferrous fumarate 140mg/5ml oral solution | £3.92 | 200 ml | 1 Oct 2026 |
| NHS Drug Tariff | Ferrous fumarate 140mg/5ml oral solution sugar free | £5.33 | 300 ml | 1 Oct 2026 |
| NHS Drug Tariff | Ferrous fumarate 210mg tablets | £3.45 | 84 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Ferrous fumarate 305mg capsules | £5.00 | 100 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Ferrous fumarate 322mg tablets | £1.00 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 29 Apr 2022 LO/OVRAL FE — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 29 Apr 2022 NORMINEST FE — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 29 Apr 2022 NORQUEST FE — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.